POTASSIUM CHLORIDE- potassium chloride injection, solution, concentrate
Hospira, Inc.
----------
POTASSIUM CHLORIDE
for Injection Concentrate, USP
FOR INTRAVENOUS INFUSION ONLY
MUST BE DILUTED PRIOR TO INJECTION
2 mEq/mL
Rx only
| CONCENTRATE |
|
MUST BE DILUTED BEFORE USE. |
| Pharmacy Bulk Package — Not for Direct Infusion |
DESCRIPTION
Potassium Chloride for Injection Concentrate, USP is a sterile, nonpyrogenic, concentrated solution of potassium chloride in water for injection to be administered by intravenous infusion only after dilution in a larger volume of fluid. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture service and are restricted to the preparation of admixtures for intravenous infusion.
|
Solution Characteristics |
|
|
mEq K+/mL |
2 |
|
mg potassium chloride/mL |
149 |
|
pH* |
4.6 |
|
pH range |
4.0 − 8.0 |
|
mOsmol/liter (calc.) |
4000 |
|
Specific gravity |
1.09 |
|
*Solution may contain hydrochloric acid for pH adjustment. |
|
The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for single-dose injection (after dilution). Discard unused portion of Pharmacy Bulk Package after 4 hours.
Potassium Chloride for Injection Concentrate, USP (appropriately diluted) is a parenteral fluid and electrolyte replenisher.
Potassium Chloride, USP is chemically designated KCl, a white granular powder freely soluble in water.
CLINICAL PHARMACOLOGY
Potassium is the chief cation of body cells (160 mEq/liter of intracellular water) and is concerned with the maintenance of body fluid composition and electrolyte balance. Potassium participates in carbohydrate utilization and protein synthesis, and is critical in the regulation of nerve conduction and muscle contraction, particularly in the heart. Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.
Normally about 80 to 90% of the potassium intake is excreted in the urine, with the remainder voided in the stools and, to a small extent, in perspiration. The kidney does not conserve potassium well so that during fasting, or in patients on a potassium-free diet, potassium loss from the body continues, resulting in potassium depletion. A deficiency of either potassium or chloride will lead to a deficit of the other.
INDICATIONS AND USAGE
Potassium Chloride for Injection Concentrate, USP is indicated in the treatment of potassium deficiency states when oral replacement therapy is not feasible.
CONTRAINDICATIONS
Potassium Chloride for Injection Concentrate, USP is contraindicated in diseases where high potassium levels may be encountered, and in patients with hyperkalemia, renal failure and in conditions in which potassium retention is present.
WARNINGS
To avoid potassium intoxication, do not infuse solutions rapidly. In patients with renal insufficiency, administration of potassium chloride may cause potassium intoxication and life-threatening hyperkalemia.
The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations.
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
PRECAUTIONS
General
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the use of additional electrolyte supplements, or the use of electrolyte-free dextrose solutions to which individualized electrolyte supplements may be added.
Potassium therapy should be guided primarily by serial electrocardiograms, especially in patients receiving digitalis. Serum potassium levels are not necessarily indicative of tissue potassium levels. Solutions containing potassium should be used with caution in the presence of cardiac disease, particularly in the presence of renal disease, and in such instances, cardiac monitoring is recommended.
Solutions containing dextrose should be used with caution in patients with overt or known subclinical diabetes mellitus, or carbohydrate intolerance for any reason.
If the administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result.
Usage in Pregnancy:
Animal reproduction studies have not been conducted with potassium chloride. It is also not known whether potassium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium chloride should be given to a pregnant woman only if clearly needed.
ADVERSE REACTIONS
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, hypervolemia, and hyperkalemia.
Too rapid infusion of hypertonic solutions may cause local pain and, rarely, vein irritation. Rate of administration should be adjusted according to tolerance.
Reactions reported with the use of potassium-containing solutions include nausea, vomiting, abdominal pain and diarrhea. The signs and symptoms of potassium intoxication include paresthesias of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities and cardiac arrest. Potassium deficits result in disruption of neuromuscular function, and intestinal ileus and dilatation.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
OVERDOSAGE
In the event of fluid overload during parenteral therapy, reevaluate the patient’s condition, and institute appropriate corrective treatment.
In the event of overdosage with potassium-containing solutions, discontinue the infusion immediately, and institute corrective therapy to reduce serum potassium levels.
Treatment of hyperkalemia includes the following:
-
Dextrose Injection USP, 10% or 25%, containing 10 units of crystalline insulin per 20 grams of dextrose administered intravenously, at a rate of 300 to 500 mL per hour.
-
Absorption and exchange of potassium using sodium or ammonium cycle cation exchange resin, orally and as retention enema.
-
Hemodialysis and peritoneal dialysis. The use of potassium-containing foods or medications must be eliminated. However, in cases of digitalization, too rapid a lowering of plasma potassium concentration can cause digitalis toxicity.
DOSAGE AND ADMINISTRATION
Potassium Chloride for Injection Concentrate, USP must be diluted before administration. Care must be taken to ensure there is complete mixing of the potassium chloride with the large volume fluid, particularly if soft or bag type containers are used.
The dose and rate of injection are dependent upon the individual needs of each patient.
If the serum potassium level is greater than 2.5 mEq/liter, potassium can be given at a rate not to exceed 10 mEq/hour in a concentration of up to 40 mEq/liter. The total 24-hour dose should not exceed 200 mEq.
If urgent treatment is indicated (serum potassium level less than 2.0 mEq/liter with electrocardiographic changes or paralysis) potassium chloride may be infused very cautiously at a rate of up to 40 mEq/hour. In such cases, continuous cardiac monitoring is essential. As much as 400 mEq may be administered in a 24 hour period. In critical conditions, potassium chloride may be administered in saline (unless contraindicated) rather than in dextrose-containing fluids, as dextrose may lower serum potassium levels.
Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit. See PRECAUTIONS.
Do not administer unless solution is clear and seal intact. Discard unused portion.
Directions for Proper Use of Pharmacy Bulk Package
The pharmacy bulk package is for use in a Pharmacy Admixture service only. Suspend as a unit in the laminar flow hood. A single entry through the vial closure should be made with a sterile dispensing set which allows measured dispensing of the contents. Transfer individual dose(s) to appropriate intravenous infusion solutions without delay. Use of a syringe with needle is not recommended. Multiple entries will also increase the potential of microbial and particulate contamination. The above process should be carried out under a laminar flow hood using aseptic technique. ANY UNUSED PORTION MUST BE DISCARDED WITHIN 4 HOURS.
HOW SUPPLIED
Potassium Chloride for Injection Concentrate, USP (2 mEq/mL) in the 250 mL Pharmacy Bulk Package is supplied as List 1513. NDC 0409-1513-02.
Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.
Distributed by Hospira Inc., Lake Forest, IL 60045 USA
LAB-1318-1.0
Revised: 05/2018
| POTASSIUM CHLORIDE
potassium chloride injection, solution, concentrate |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| Labeler - Hospira, Inc. (141588017) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Hospira, Inc. | 827731089 | ANALYSIS(0409-1513) | |